Navigation Links
Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)
Date:9/11/2007

s trial which could expand the application into the larger indolent NHL market."

Pixantrone in Indolent NHL

Preliminary results from a phase I/II study of pixantrone combined with fludarabine, dexamethasone, and rituximab for patients with relapsed indolent NHL were presented at the American Society of Hematology (ASH) annual meeting in December 2006. Among the 27 patients evaluable for response, study results showed the FPD-R regimen with pixantrone produced an 89 percent overall response rate (ORR) by the Cheson criteria, including 70 percent of patients experiencing a complete response/unconfirmed complete response (CR/uCR; 63 percent, CR and seven percent, u/CR). The estimated median duration of response was 25 months and the estimated progression-free survival rate at three years was 50.4 percent.

In addition, pixantrone was studied in a randomized clinical trial for indolent NHL patients comparing pixantrone in combination with rituximab to rituximab alone, with time to progression (TTP) as the primary efficacy endpoint. The study of 38 relapsed or refractory patients receiving the combination of rituximab and pixantrone had a 60 percent overall improvement in TTP compared to rituximab alone. [SC1] The median TTP estimate for the pixantrone/rituximab recipients was 13.0 months compared to 8.1 months for rituximab alone (hazard ratio 0.13, log rank p<0.001).

Pixantrone in Aggressive NHL

Pixantrone is the subject of two ongoing studies in aggressive NHL, a phase III single agent trial, known as EXTEND (PIX301) and a phase II/III combination study, known as RAPID (PIX203). The EXTEND trial explores the role of single agent treatment as a salvage regimen in patients with relapsed aggressive NHL who have failed at least two prior treatment regimens. Patients are randomized to receive either pixantrone or another single-agent drug of physician's choice currently used for the treatment of this patient population.

The RAPID trial is
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... 17, 2014 ... ) has announced the addition of ... American Automated External Defibrillators (AED) Market" ... http://photos.prnewswire.com/prnh/20130307/600769) ,The report North American Automated ... market of devices based upon following ...
(Date:10/17/2014)... , October 17, 2014 ... Pharmaceuticals Inc. (NASDAQ: ARNA ), NPS Pharmaceuticals ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: ... CPRX). Free research on these five companies can be ... markets on Thursday, October 16, 2014, ended on a ...
(Date:10/17/2014)... , Oct. 17, 2014  Talyst, a market leader ... LeadingAge Annual Meeting in Nashville, TN. ... the market leading solution for onsite, remote medication dispensing. ... care facilities to safely and securely dispense medication onsite, ... first dose, helps ensure that the correct medication gets ...
Breaking Medicine Technology:Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Talyst Exhibits at LeadingAge Annual Meeting 2
... NATICK, Mass., Jan. 4, 2011 Boston Scientific Corporation ... of its acquisition of Sadra Medical, Inc. of Los ... announced on November 19, 2010.  Under the terms of ... the remaining 86 percent of Sadra Medical,s equity not ...
... and Company) (NYSE: BDX ), a leading global medical ... Annual J. P. Morgan Healthcare Conference on Monday, January 10, 2011, ... BD,s presentation can be accessed from the BD corporate website at ... January 17, 2011.   About BDBD is ...
Cached Medicine Technology:Boston Scientific Completes Acquisition of Sadra Medical 2Boston Scientific Completes Acquisition of Sadra Medical 3Boston Scientific Completes Acquisition of Sadra Medical 4
(Date:10/20/2014)... (PRWEB) October 20, 2014 JZ Fitness, ... nutritional coaching, corporate wellness programming, authorship, international lecturing and ... excited to announce the release of the JZ Fitness ... many years of coaching thousands of individuals on nutrition, ... app that does not require calorie counting or cumbersome ...
(Date:10/20/2014)... 20, 2014 Principle Business Enterprises, a ... in manufacturing top-of-the-line absorbent products. The company has ... most popular brand, Tranquility® Premium Protection absorbent products. ... website, gave its packaging a new look, and is ... message to the public. , The new website, developed ...
(Date:10/20/2014)... 20, 2014 Myoderm ... Assistant Director of their CentralSource service. ... the innovative turnkey drug sourcing, distribution, and management ... over 12 years of industry experience, in both ... the peak of their international success to help ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Succeed is proud ... local companies who participated in the Every Body Walk! ... a public awareness project that encourages workers to be more ... Step 10,000 Program, which concluded at the end of September, ... of cities and metro areas. Participating companies gave their ...
(Date:10/20/2014)... 20, 2014 National Teen Driver Safety Week ... American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is ... parents of teen drivers to talk to their teens and ... Motor vehicle crashes are the leading cause of death for ... in fatal crashes, and 859 (42%) of those teen drivers ...
Breaking Medicine News(10 mins):Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2
... Nearly one in three women who have breast cancer ... additional surgery after the tumor is evaluated by a pathologist. ... Cancer Center cuts that number drastically by having pathologists on-site ... immediately after they are removed. Meanwhile, the surgeon and patient ...
... News) -- Drug-free recovery housing and day treatment programs ... who have gone through detoxification will be able to ... abuse includes both the use of illegal drugs such ... such as OxyContin, Vicodin and Percocet. Opioid addicts ...
... alone, approximately 6 million people suffer from an irregular ... with age, it is predicted that 15.9,million Americans will ... of AF is stroke, but,a new device from Boston ... Atritech, now part of Boston Scientific, developed the WATCHMAN ...
... MONDAY, Feb. 27 (HealthDay News) -- Many people with stable ... work just as well, a new study suggests. The ... a clogged artery. As many as three-quarters of these operations ... professor of medicine at Stony Brook University Medical Center in ...
... A great deal has been learned in the ten years ... (WHI). Hormone therapy (HT) remains the most effective treatment available ... a growing body of evidence that formulation, route of administration, ... effects. It is essential to evaluate a personal ...
... the country tripled to nearly three per year between 1994 ... 15 years, according to an analysis of weather conditions and ... Georgia researchers. The scientists built a detailed database ... well as the height, weight and position for 58 football ...
Cached Medicine News:Health News:Fewer women need repeat breast cancer surgeries with new service at University of Michigan 2Health News:Drug-Free Housing Helps Heroin, Oxycontin Addicts Recover 2Health News:Stroke-preventing technology demonstrated in JoVE 2Health News:Stents No Better Than Medicine for Stable Heart Disease, Study Says 2Health News:Stents No Better Than Medicine for Stable Heart Disease, Study Says 3Health News:The North American Menopause Society (NAMS) reassures many women 2Health News:Deaths triple among football players, morning temperatures thought to play a role 2